Clare M. Murray

发表

Correction for Savadjiev et al., Heart wall myofibers are arranged in minimal surfaces to optimize organ function

J. Pouysségur, S. Critchlow, D. Roux, 2012, Proceedings of the National Academy of Sciences.

Mechanism of Action of Inhibition of Allergic Immune Responses by a Novel Antedrug TLR7 Agonist

Y. Ueda, H. Tomizawa, M. Biffen, 2012, The Journal of Immunology.

TLR7 Stimulation of APCs Results in Inhibition of IL-5 through Type I IFN and Notch Signaling Pathways in Human Peripheral Blood Mononuclear Cells

H. Tomizawa, M. Biffen, Clare M. Murray, 2013, The Journal of Immunology.

The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein

A. Halestrap, Marieangela C. Wilson, Marieangela C Wilson, 2010, The Biochemical journal.

AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10

A. Halestrap, Marieangela C. Wilson, A. Davies, 2009, The Biochemical journal.

755 Pharmacologic tumor PD-L1 depletion reduces Chk2 content and sensitizes tumors to small molecule Chk1 DNA damage repair inhibitors

T. Curiel, Anand V. R. Kornepati, Clare M. Murray, 2021, Journal for ImmunoTherapy of Cancer.

The Specific Monocarboxylate Transporter-1 (MCT-1) Inhibitor, AR-C117977, Induces Donor-Specific Suppression, Reducing Acute and Chronic Allograft Rejection in the Rat

B. Veress, H. Ekberg, D. Donald, 2007, Transplantation.

AZD8848/DSP-3025 Is A Novel Potent TLR7 Agonist Ante-Drug That Demonstrates Negligible Systemic Activity And A Prolonged Period Of Control After Cessation Of Weekly Dosing In A Brown Norway Rat Ovalbumin Challenge Model

Douglas Ferguson, M. Biffen, Clare M. Murray, 2010, ATS 2010.

Peripheral Blood Mononuclear Cells Notch Signaling Pathways in Human Inhibition of IL-5 through Type I IFN and TLR7 Stimulation of APCs Results in

H. Tomizawa, M. Biffen, Clare M. Murray, 2013 .

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents

T. Curiel, Anand V. R. Kornepati, J. Conejo-Garcia, 2022, International journal of molecular sciences.

TLR7 Agonist Immune Responses by a Novel Antedrug Mechanism of Action of Inhibition of Allergic

H. Tomizawa, M. Biffen, Clare M. Murray, 2012 .

Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)

Paul D. Smith, A. Logié, S. Critchlow, 2012 .

The Specific Monocarboxylate Transporter (MCT1) Inhibitor, AR-C117977, a Novel Immunosuppressant, Prolongs Allograft Survival in the Mouse

I. Binet, K. Wood, D. Donald, 2007, Transplantation.

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

J. Pouysségur, S. Critchlow, D. Roux, 2011, Proceedings of the National Academy of Sciences.

Interleukin‐4 can induce interleukin‐4 production in dendritic cells

A. Maroof, S. Knight, Clare M. Murray, 2006, Immunology.

900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner

T. Curiel, P. Sung, L. Byers, 2021, Journal for ImmunoTherapy of Cancer.

Monocarboxylate transporter MCT1 is a target for immunosuppression

A. Ross, Leslie R Evans, A. Jackson, 2005, Nature chemical biology.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

M. Firth, Paul D. Smith, Kate F. Byth, 2017, Oncotarget.

Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT‐1

H. Ekberg, D. Donald, Z. Qi, 2013, Transplant international : official journal of the European Society for Organ Transplantation.

10th Anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit

M. Braddock, Clare M. Murray, 2006, Expert opinion on investigational drugs.

Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.

A. Davis, D. Ferguson, L. Kingston, 2006, Bioorganic & medicinal chemistry letters.